Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
about
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.The role of biosimilars in value-based oncology careIncidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
P2860
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@en
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@nl
type
label
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@en
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@nl
prefLabel
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@en
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@nl
P2093
P2860
P1476
Cost-efficiency analyses for t ...... induced (febrile) neutropenia.
@en
P2093
Ali McBride
Ivo Abraham
Karen MacDonald
Kim Campbell
Mohan Bikkina
Sanjeev Balu
P2860
P304
P356
10.1080/13696998.2017.1358173
P407
P577
2017-07-19T00:00:00Z